Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZOCT
4626
Innovator Equity Defined Protection ETF - 1 Yr October
ZOCT
$105M
| $59.7K | ﹤0.01% |
2,223
-3,343
| -60% | -$89.3K |
|
4627
Vanguard ESG US Stock ETF
ESGV
$13.6B
| $59.6K | ﹤0.01% |
+493
| New | +$59.1K |
|
4628
Value Line
VALU
$375M
| $59.5K | ﹤0.01% |
1,547
+415
| +37% | +$15.7K |
|
4629
Sprott Physical Silver Trust
PSLV
$13.5B
| $59.1K | ﹤0.01% |
2,500
-46,656
| -95% | -$855K |
|
4630
Acrivon Therapeutics
ACRV
$74M
| $58.8K | ﹤0.01% |
24,402
+4,437
| +22% | +$9.64K |
|
4631
Cognyte Software
CGNT
$692M
| $58.6K | ﹤0.01% |
6,233
+216
| +4% | +$1.87K |
|
|
MSB
4632
Mesabi Trust
MSB
$309M
| $57.8K | ﹤0.01% |
+1,500
| New | +$50.8K |
|
4633
Novartis
NVS
$294B
| $56.4K | ﹤0.01% |
409
-154
| -27% | -$20.2K |
|
4634
Suburban Propane Partners
SPH
$1.17B
| $55.8K | ﹤0.01% |
3,007
-135
| -4% | -$2.53K |
|
4635
Seanergy Maritime Holdings
SHIP
$345M
| $55.7K | ﹤0.01% |
6,039
-13,323
| -69% | -$121K |
|
4636
Neumora Therapeutics
NMRA
$315M
| $55.4K | ﹤0.01% |
30,924
+20,683
| +202% | +$45.3K |
|
4637
Traeger
COOK
$178M
| $55.3K | ﹤0.01% |
1,024
+93
| +10% | +$4.53K |
|
4638
Freightos
CRGO
$64.6M
| $55K | ﹤0.01% |
+24,138
| New | +$78.4K |
|
4639
Innovator US Equity Accelerated 9 Buffer ETF January
XBJA
$88.5M
| $54.7K | ﹤0.01% |
1,712
-238
| -12% | -$7.52K |
|
4640
Global E Online
GLBE
$6.86B
| $54.6K | ﹤0.01% |
1,389
-326,304
| -100% | -$12.1M |
|
4641
Silicom
SILC
$264M
| $53.9K | ﹤0.01% |
3,670
+927
| +34% | +$14.5K |
|
4642
FT Vest US Equity Deep Buffer ETF August
DAUG
$374M
| $53.8K | ﹤0.01% |
1,214
+884
| +268% | +$38.8K |
|
4643
Innovator US Equity Power Buffer ETF November
PNOV
$895M
| $53.7K | ﹤0.01% |
1,286
-2,865
| -69% | -$119K |
|
4644
AMREP Corp
AXR
$115M
| $52.5K | ﹤0.01% |
2,795
+2,478
| +782% | +$53.5K |
|
4645
Mobile Infrastructure Corp
BEEP
$114M
| $52.2K | ﹤0.01% |
20,468
-601
| -3% | -$1.88K |
|
4646
HSBC
HSBC
$355B
| $52K | ﹤0.01% |
661
-14,424
| -96% | -$1.03M |
|
4647
Innovator US Equity Power Buffer ETF July
PJUL
$1.29B
| $51.9K | ﹤0.01% |
1,117
+1,004
| +888% | +$46.1K |
|
4648
CALL
Western Digital
WDC
$151B
| $51.7K | ﹤0.01% |
300
-53,100
| -99% | -$8.05M |
|
4649
Torrid Holdings
CURV
$239M
| $51.6K | ﹤0.01% |
52,769
+5,195
| +11% | +$6.64K |
|
4650
MediciNova
MNOV
$65M
| $51.6K | ﹤0.01% |
39,400
-49,215
| -56% | -$67.9K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.